A new proposed rule from the Trump administration aims to make it easier for employers to offer coverage of fertility treatments, as part of larger efforts to expand access to fertility services including in-vitro fertilization. The new rule released Sunday from the Department of Labor would create a new exempted insurance benefit — in the same category as dental and vision benefit coverage— for treating infertility. Exempted benefits don’t have ...

Gov. Gavin Newsom announced last week that California is expanding behavioral health treatment capacity statewide through a series of new and ongoing projects aimed at increasing mental health and substance use disorder services.

More access to affordable weight-loss medications is coming this summer for adults on Medicare. Starting in July, certain Medicare enrollees can pay $50 a month for specific prescription GLP–1 medications, according to the Centers for Medicare and Medicaid Services. Medicare announced the pilot program for the popular weight loss medications on Wednesday. The Medicare GLP-1 Bridge program will run ...

HHS Secretary Robert F. Kennedy Jr. recently announced an action plan aimed at reducing the overprescribing of psychiatric medications. “Today, we take clear and decisive action to confront our nation’s mental health crisis by addressing the overuse of psychiatric medications — especially among children,” he said last week. “We will support patient autonomy; require informed ...

Employers want greater transparency in their pharmacy benefits, with many viewing a model that eschews rebates as a key way to get there, according to a new survey. The Penta Group surveyed 300 benefits decision-makers, half of whom hailed from companies with 1,000 to 4,999 workers and half from companies with more than 5,000 employees, for Evernorth. ...

Following a series of “most favored nation” (MFN) pricing deals with 17 large pharma companies, the Trump administration released a report Tuesday projecting a potential $529 billion in savings from the policy over the next decade. That $529 billion figure comes from an estimation of prospective MFN, in which biopharma companies pledge to launch all future U.S. ...